Usefulness of Low-dose Pimobendan for Patients with Chronic Heart Failure

Usefulness of Low-dose Pimobendan for Patients with Chronic Heart Failure - LDP-CHF study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009687

Enrollment

Registered

2013-01-04

Start date

2013-01-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure patients receiving treatment in the hospital for heart failure hospitalization, transition to outpatient therapy

Interventions

Administration of low-dose Pimobendan (1.25 mg/day ~2.5mg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with non-ischemic heart disease 2. Serum Creatinine less than 2.5 mg/dl 3. Patients or legal representatives who agree with the study and sign agreement in writing

Exclusion criteria

Exclusion criteria: 1. Patients with hypertrophic obstructive cardiomyopathy and/or obstructive heart valve disease 2. Patients with acute myocardial infarction. 3. Patients with advanced atrioventricular block and/or and lethal arrhythmia. 4. Patients with severe cerebrovascular disease 5. Patients with severe hepatic and renal failure 6. Patients with a possibility of pregnancy, pregnant or lactating 7. Patients who are judeged not to eligible for partitipation to this study by attending physician

Design outcomes

Primary

Measure	Time frame
Symptoms due to chronic heart failure, exercise capacity	—

Countries

Japan

Contacts

Public ContactTakashi Iwase

Tokushima University Hospital Department of Cardiology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026